Tech Company Financing Transactions
CellCentric Funding Round
CellCentric secured a $120 million Series C venture capital round on 5/19/2025. Backers included RA Capital Management, Avego Management and BrightEdge.
Transaction Overview
Company Name
Announced On
5/19/2025
Transaction Type
Venture Equity
Amount
$120,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to: Accelerate the Phase II/III study in heavily pretreated multiple myeloma patients, with the potential to support an accelerated approval.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Neue Strasse 95 Industriepark Nabern
Kirchheim, 73230
DE
Kirchheim, 73230
DE
Phone
Undisclosed
Website
Email Address
Overview
CellCentric is a clinical stage biotech company; science driven, patient focused. We lead in the inhibition of p300/CBP to treat multiple specific cancer types. Our aim is to develop our first-in-class drug, inobrodib, as quickly and as effectively as possible for the benefit of patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Matthias Jurytko
Chief Financial Officer
Niklas Ekström
Browse more venture capital transactions:
Prev: 5/18/2025: VUZ venture capital transaction
Next: 5/19/2025: Envoke venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs